Results 201 to 210 of about 565,222 (249)
Some of the next articles are maybe not open access.
Hodgkin lymphoma: 2023 update on diagnosis, risk‐stratification, and management
American journal of hematology/oncology, 2022Hodgkin lymphoma (HL) is an uncommon B‐cell lymphoid malignancy affecting 8540 new patients annually and representing approximately 10% of all lymphomas in the United States.
S. Ansell
semanticscholar +1 more source
Nursing Standard, 2004
Hodgkin's lymphoma is a malignant disease of the lymphatic system. This article gives an overview of the disease process and the classification and staging of Hodgkin's lymphoma. The nursing care and psychological support of these patients during radiotherapy and chemotherapy treatment are also discussed.
Sylvia, Cole, Kathleen, Dunne
openaire +2 more sources
Hodgkin's lymphoma is a malignant disease of the lymphatic system. This article gives an overview of the disease process and the classification and staging of Hodgkin's lymphoma. The nursing care and psychological support of these patients during radiotherapy and chemotherapy treatment are also discussed.
Sylvia, Cole, Kathleen, Dunne
openaire +2 more sources
The Lancet, 2003
Hodgkin's lymphoma was first described in 1832, but the nature of the pathognomic Reed-Sternberg cell, on which diagnosis of the disease is based, has only been elucidated in the past few years. Radiotherapy has been used to treat localised disease since the 1940s, and in the 1960s, effective combination chemotherapy regimens were introduced for ...
Lynny, Yung, David, Linch
openaire +2 more sources
Hodgkin's lymphoma was first described in 1832, but the nature of the pathognomic Reed-Sternberg cell, on which diagnosis of the disease is based, has only been elucidated in the past few years. Radiotherapy has been used to treat localised disease since the 1940s, and in the 1960s, effective combination chemotherapy regimens were introduced for ...
Lynny, Yung, David, Linch
openaire +2 more sources
Critical Reviews in Oncology/Hematology, 2013
Hodgkin lymphoma (HL) is a curable malignancy which shows a bimodal curve in incidence in economically developed countries; there is a putative association with Epstein-Barr virus. The WHO 2008 classification schema recognises two histological types of HL: the nodular lymphocyte predominant and the "classic" HL.
GOBBI, PAOLO +3 more
openaire +3 more sources
Hodgkin lymphoma (HL) is a curable malignancy which shows a bimodal curve in incidence in economically developed countries; there is a putative association with Epstein-Barr virus. The WHO 2008 classification schema recognises two histological types of HL: the nodular lymphocyte predominant and the "classic" HL.
GOBBI, PAOLO +3 more
openaire +3 more sources
European Journal of Cancer, 1998
To review the etiology, epidemiology, classification, diagnosis, staging, prognosis, treatment, and nursing implications of non-Hodgkin's lymphoma.Research studies, review articles, and book chapters pertaining to non-Hodgkin's lymphoma.Non-Hodgkins's lymphomas are a heterogeneous group of lympho-proliferative disorders, increasing in frequency, for ...
B A, Bilodeau, K L, Fessele
openaire +4 more sources
To review the etiology, epidemiology, classification, diagnosis, staging, prognosis, treatment, and nursing implications of non-Hodgkin's lymphoma.Research studies, review articles, and book chapters pertaining to non-Hodgkin's lymphoma.Non-Hodgkins's lymphomas are a heterogeneous group of lympho-proliferative disorders, increasing in frequency, for ...
B A, Bilodeau, K L, Fessele
openaire +4 more sources
The Lancet, 2017
Lymphomas can affect any organ in the body, present with a wide range of symptoms, and be seen by primary care physicians and physicians from most specialties. They are traditionally divided into Hodgkin's lymphoma (which accounts for about 10% of all lymphomas) and non-Hodgkin lymphoma, which is the topic of this Seminar.
Zeppa P., Cozzolino I.
openaire +4 more sources
Lymphomas can affect any organ in the body, present with a wide range of symptoms, and be seen by primary care physicians and physicians from most specialties. They are traditionally divided into Hodgkin's lymphoma (which accounts for about 10% of all lymphomas) and non-Hodgkin lymphoma, which is the topic of this Seminar.
Zeppa P., Cozzolino I.
openaire +4 more sources
Current Problems in Cancer, 2006
An estimated 8,490 new cases of Hodgkin’s lymphoma were diagnosed in the USA in 2010. Reed–Sternberg cells are the malignant cells in classical Hodgkin’s lymphoma (CD15+, CD30+, and CD45−). In nodular lymphocyte-predominant Hodgkin’s lymphoma (NLPHL), these cells express B-cell markers (CD20+, CD79a+, and CD45+) and are CD15− and CD30 ...
Richard W, Tsang +2 more
openaire +2 more sources
An estimated 8,490 new cases of Hodgkin’s lymphoma were diagnosed in the USA in 2010. Reed–Sternberg cells are the malignant cells in classical Hodgkin’s lymphoma (CD15+, CD30+, and CD45−). In nodular lymphocyte-predominant Hodgkin’s lymphoma (NLPHL), these cells express B-cell markers (CD20+, CD79a+, and CD45+) and are CD15− and CD30 ...
Richard W, Tsang +2 more
openaire +2 more sources
Medicine, 2018
This edition describes the increased use of PET scanning in staging and follow-up. Chapters discuss current treatment options—including combination chemotherapy, radiation therapy, novel treatment techniques, and hematopoietic stem cell transplantation ...
D. Wrench, Paul Fields
semanticscholar +1 more source
This edition describes the increased use of PET scanning in staging and follow-up. Chapters discuss current treatment options—including combination chemotherapy, radiation therapy, novel treatment techniques, and hematopoietic stem cell transplantation ...
D. Wrench, Paul Fields
semanticscholar +1 more source
Current Opinion in Oncology, 2013
Despite the advances in the treatment of Hodgkin Lymphoma, patients with refractory disease still have a poor prognosis. Hodgkin Lymphoma can be refractory at first diagnosis or might become refractory later in the course of treatment. Both situations represent a therapeutic challenge.Intensified chemotherapy with BEACOPP escalated has been evaluated ...
Bastian, von Tresckow, Andreas, Engert
openaire +2 more sources
Despite the advances in the treatment of Hodgkin Lymphoma, patients with refractory disease still have a poor prognosis. Hodgkin Lymphoma can be refractory at first diagnosis or might become refractory later in the course of treatment. Both situations represent a therapeutic challenge.Intensified chemotherapy with BEACOPP escalated has been evaluated ...
Bastian, von Tresckow, Andreas, Engert
openaire +2 more sources
Hematological Oncology, 2023
Abstract Classic Hodgkin lymphoma (HL) is rare disease, with an incidence of approximately 85,000 patients globally per year and a predilection for adolescents and young adults (ages 15–39). Since the introduction of combination chemotherapy in the 1960's and radiation dating back to the early 1900's, therapeutic options and by ...
Justine Kahn +7 more
openaire +2 more sources
Abstract Classic Hodgkin lymphoma (HL) is rare disease, with an incidence of approximately 85,000 patients globally per year and a predilection for adolescents and young adults (ages 15–39). Since the introduction of combination chemotherapy in the 1960's and radiation dating back to the early 1900's, therapeutic options and by ...
Justine Kahn +7 more
openaire +2 more sources